Association between FBP1 and hypoxia-related gene expression in clear cell renal cell carcinoma.
Fructose-1,6-bisphosphatase 1 (FBP1) is a rate-limiting enzyme in gluconeogenesis. Recently, the catalytic activity-independent function of FBP1, hypoxia-induced factor (HIF) repression in the nucleus, was identified. The aim of the present study was to investigate the association between FBP1 and hypoxia-related gene expression in clear cell renal cell carcinoma (ccRCC). The protein expression levels of FBP1, HIF-1α, HIF-2α, erythropoietin (EPO) and carbonic anhydrase IX (CA9) were assessed by immunohistochemical staining of ccRCC paraffin blocks from 123 patients using the tissue microarray technique. The expression level of FBP1 was then correlated with various clinicopathological factors, and the protein expression levels of HIF-1α, HIF-2α, EPO and CA9. Clinicopathological factors, including age, gender, T stage and Fuhrman grade, were not significantly different between patients with low and high FBP1 expression in ccRCC (P>0.05). FBP1 protein expression level was significantly correlated with the expression levels of HIF-1α (P=0.005) and EPO (P=0.010), but not significantly correlated with the expression levels of HIF-2α (P=0.123) and CA9 (P=0.513) in ccRCC tissues. The current findings confirm the association between FBP1 and hypoxia-related gene expression, and may facilitate understanding of the mechanisms of ccRCC tumorigenesis.
Department of Urology, Peking University First Hospital, Beijing 100034, P.R. China; Institute of Urology, Peking University, Beijing 100034, P.R. China; National Urological Cancer Center, Peking University, Beijing 100034, P.R. China.
Xiang-Hui
XH
Ning
Department of Urology, Peking University First Hospital, Beijing 100034, P.R. China; Institute of Urology, Peking University, Beijing 100034, P.R. China; National Urological Cancer Center, Peking University, Beijing 100034, P.R. China.
Teng
T
Li
Department of Urology, Peking University First Hospital, Beijing 100034, P.R. China; Institute of Urology, Peking University, Beijing 100034, P.R. China; National Urological Cancer Center, Peking University, Beijing 100034, P.R. China.
Yan-Qing
YQ
Gong
Department of Urology, Peking University First Hospital, Beijing 100034, P.R. China; Institute of Urology, Peking University, Beijing 100034, P.R. China; National Urological Cancer Center, Peking University, Beijing 100034, P.R. China.
Qun
Q
He
Department of Urology, Peking University First Hospital, Beijing 100034, P.R. China; Institute of Urology, Peking University, Beijing 100034, P.R. China; National Urological Cancer Center, Peking University, Beijing 100034, P.R. China.
Q I
QI
Shen
Department of Urology, Peking University First Hospital, Beijing 100034, P.R. China; Institute of Urology, Peking University, Beijing 100034, P.R. China; National Urological Cancer Center, Peking University, Beijing 100034, P.R. China.
Shuang-He
SH
Peng
Department of Urology, Peking University First Hospital, Beijing 100034, P.R. China; Institute of Urology, Peking University, Beijing 100034, P.R. China; National Urological Cancer Center, Peking University, Beijing 100034, P.R. China.
Jiang-Yi
JY
Wang
Department of Urology, Peking University First Hospital, Beijing 100034, P.R. China; Institute of Urology, Peking University, Beijing 100034, P.R. China; National Urological Cancer Center, Peking University, Beijing 100034, P.R. China.
Jin-Chao
JC
Chen
Department of Urology, Peking University First Hospital, Beijing 100034, P.R. China; Institute of Urology, Peking University, Beijing 100034, P.R. China; National Urological Cancer Center, Peking University, Beijing 100034, P.R. China.
Ying-Lu
YL
Guo
Department of Urology, Peking University First Hospital, Beijing 100034, P.R. China; Institute of Urology, Peking University, Beijing 100034, P.R. China; National Urological Cancer Center, Peking University, Beijing 100034, P.R. China.
Kan
K
Gong
clear cell renal cell carcinoma; fructose-1,6-bisphosphatase; hypoxia-related genes